The Effect of BMS-986195 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects

Trial Profile

The Effect of BMS-986195 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs BMS 986195 (Primary) ; Ethinylestradiol/norethisterone
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 16 Jan 2018 Planned End Date changed from 26 Dec 2017 to 31 Jan 2018.
    • 16 Jan 2018 Planned primary completion date changed from 25 Dec 2017 to 30 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top